全文获取类型
收费全文 | 1009篇 |
免费 | 75篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 58篇 |
妇产科学 | 8篇 |
基础医学 | 86篇 |
口腔科学 | 29篇 |
临床医学 | 177篇 |
内科学 | 217篇 |
皮肤病学 | 12篇 |
神经病学 | 27篇 |
特种医学 | 245篇 |
外科学 | 49篇 |
综合类 | 21篇 |
预防医学 | 30篇 |
眼科学 | 9篇 |
药学 | 57篇 |
中国医学 | 5篇 |
肿瘤学 | 58篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 24篇 |
2017年 | 12篇 |
2016年 | 20篇 |
2015年 | 20篇 |
2014年 | 26篇 |
2013年 | 28篇 |
2012年 | 24篇 |
2011年 | 22篇 |
2010年 | 35篇 |
2009年 | 55篇 |
2008年 | 27篇 |
2007年 | 10篇 |
2006年 | 17篇 |
2005年 | 12篇 |
2004年 | 13篇 |
2003年 | 19篇 |
2002年 | 17篇 |
2001年 | 16篇 |
2000年 | 14篇 |
1999年 | 12篇 |
1998年 | 50篇 |
1997年 | 54篇 |
1996年 | 67篇 |
1995年 | 48篇 |
1994年 | 44篇 |
1993年 | 48篇 |
1992年 | 15篇 |
1991年 | 8篇 |
1990年 | 15篇 |
1989年 | 37篇 |
1988年 | 32篇 |
1987年 | 36篇 |
1986年 | 35篇 |
1985年 | 24篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 26篇 |
1981年 | 15篇 |
1980年 | 9篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 14篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1091条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Kath R.; Hoftken K.; Otte C.; Metz K.; Scheulen M. E.; Hulskamp F.; Seeber S. 《Annals of oncology》1993,4(7):585-590
BACKGROUND:: A soluble 105 kD neu-related protein is detectable in conditionedmedium from breast cancer cells expressing the neu-oncogeneproduct and in serum of nude mice bearing tumors that overexpressneu-oncogene PATIENTS AND METHODS:: In 100 patients with primary (n - 33) relapse-free (n - 6) andmetastatic (n - 61) breast carcinoma the serum levels of thesoluble new-related protein were investigated by ELISA techniques.Median age was 57 years, range 2689 years. RESULTS:: The neu-protein serum levels were below 40 HNU/ml (human neu-antigenunit) in 72 patients and 40 or more HNU/ml in 28 patients. In30 patients with primary breast carcinoma, tested before mastectomy,all serum- neu-protein samples were negative. However, 26 of61 metastazised patients (43%) were serum-neu-protein-positive.In disseminated disease (n 61), serum-neu-protein-positivitywas more likely to be seen in patients with visceral metastases(18/33 54%), than in patients with nonvisceral metastases(8/28 28%). Furthermore, monitoring of the serum-neu-proteinlevels reflected clinical course. For 53 patients original paraffin-embeddedtumor material was available for studying immunohistochemicalneu-protein expression. In 39/53 (73%) patients immunohistochemicaland ELISA data showed corresponding results. In 27/30 (90%)patients, from whom sera and tissue could be obtained at thesame time at primary mastectomy, results of immunohistochemistryin primary tumor and serum ELISA were negative and mutuallyconfirmatory. However, the other three patients were positivefor immunohistochemical neu-protein expression in primary tumorbut negative for serum-neu-protein expression. CONCLUSIONS:: Our results suggest that patients with advanced breast cancerand an elevated serum-neu-protein level may have a poor clinicaloutcome. This test might be a useful tool for monitoring patientswith advanced breast carcinoma, but not those with early disease.Further prospective studies are warranted to elucidate the questionof whether this test can contribute to determining prognosisand treatment strategies. breast carcinoma, c-erb-B2, HER-2, neu, oncogene, pl85 相似文献
3.
4.
5.
6.
7.
8.
9.
10.